 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| IVX-A12 / AstraZeneca
Trial completion: A Study of IVX-A12 in Adults Participants (clinicaltrials.gov) - Apr 28, 2025
P2, N=143, Completed, Sponsor: Icosavax, Inc.
Active, not recruiting --> Completed
- Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-like Particle Protein Subunit Combination Vaccine in 60 (Halls JK) - Sep 4, 2024 - Abstract #IDWeek2024IDWEEK_2584;
- |||| IVX-A12 / AstraZeneca
New P2 trial: A Study of IVX-A12 in Adults Participants (clinicaltrials.gov) - Jul 1, 2024
P2, N=143, Active, not recruiting, Sponsor: Icosavax, Inc.
- || IVX-A12 / AstraZeneca
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age (clinicaltrials.gov) - Apr 12, 2024
P2, N=264, Active, not recruiting, Sponsor: Icosavax, Inc.
Active, not recruiting --> Completed Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: May 2024 --> Jul 2025
- || IVX-A12 / AstraZeneca
Phase classification, Trial primary completion date: A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age (clinicaltrials.gov) - Mar 5, 2024
P2, N=264, Active, not recruiting, Sponsor: Icosavax, Inc.
Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: May 2024 --> Jul 2025 Phase classification: P2a --> P2 | Trial primary completion date: Oct 2023 --> May 2024
- ||| IVX-A12 / AstraZeneca
Trial completion, Trial primary completion date: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (clinicaltrials.gov) - Mar 5, 2024
P1, N=140, Completed, Sponsor: Icosavax, Inc.
Phase classification: P2a --> P2 | Trial primary completion date: Oct 2023 --> May 2024 Active, not recruiting --> Completed | Trial primary completion date: Jan 2023 --> Jan 2024
- ||| IVX-A12 / AstraZeneca
Enrollment closed: A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age (clinicaltrials.gov) - Jul 5, 2023
P2a, N=264, Active, not recruiting, Sponsor: Icosavax, Inc.
Active, not recruiting --> Completed | Trial primary completion date: Jan 2023 --> Jan 2024 Recruiting --> Active, not recruiting
- || IVX-A12 / AstraZeneca
Enrollment closed: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (clinicaltrials.gov) - Jun 18, 2023
P1, N=120, Active, not recruiting, Sponsor: Icosavax, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| IVX-A12 / AstraZeneca
New P2a trial: A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age (clinicaltrials.gov) - Jun 15, 2023
P2a, N=250, Recruiting, Sponsor: Icosavax, Inc.
- | IVX-A12 / AstraZeneca
New P1 trial: Safety and Immunogenicity of IVX-A12 in Healthy Older Adults (clinicaltrials.gov) - Dec 23, 2022
P1, N=120, Recruiting, Sponsor: Icosavax, Inc.